PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Addition of herbal formulae containing Fuling to hypoglycemic agents reduced fasting blood glucose [PMID:36455062].
Ethanol extracts of the surface layer improved acute kidney injury, diabetic kidney disease, and nephrotic syndrome [PMID:39482471].
Poria cocos polysaccharides (PCP) reduced body weight, adipose tissue mass, and improved glucose tolerance in obese mice [PMID:40484558].
PCP treatment alleviated myocardial injury and reduced apoptosis and inflammation [PMID:40769943].
Water-soluble PCP alleviated hepatic injury and reduced lipid accumulation in mice via gut microbiota modulation [PMID:41075893].
Evidence summary
PubMed sources
- 1.PMID: 39482471 (2025) — Poria cocos: traditional uses, triterpenoid components and their renoprotective pharmacology. · Acta pharmacologica Sinica
- 2.PMID: 37788785 (2024) — Fuling-Zexie formula attenuates hyperuricemia-induced nephropathy and inhibits JAK2/STAT3 signaling and NLRP3 inflammasome activation in mice. · Journal of ethnopharmacology
- 3.PMID: 40484558 (2025) — Poria cocos polysaccharides alleviate obesity-related adipose tissue insulin resistance via gut microbiota-derived short-chain fatty acids activation of FGF21/PI3K/AKT signaling. · Food research international (Ottawa, Ont.)
- 4.PMID: 36273747 (2023) — Qi Gong Wan ameliorates adipocyte hypertrophy and inflammation in adipose tissue in a PCOS mouse model through the Nrf2/HO-1/Cyp1b1 pathway: Integrating network pharmacology and experimental validation in vivo. · Journal of ethnopharmacology
- 5.PMID: 35938080